NORAD promotes multiple myeloma cell progression via BMP6/P-ERK1/2 axis

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Multiple myeloma (MM) is an incurable hematologic malignancy.
• Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer.
• The function and clinical significance of NORAD in MM are currently unknown.

Purpose of the Study:

• To investigate the biological role and clinical value of NORAD in multiple myeloma.
• To elucidate the underlying molecular mechanisms of NORAD's action in MM.

Main Methods:

• NORAD expression was quantified in MM patients and healthy donors using qPCR.
• NORAD was knocked down in MM cell lines via lentiviral transfection.
• Cellular effects (apoptosis, cell cycle, proliferation) were assessed using flow cytometry, CCK8, EDU assays, and Western blot.
• Gene expression profiling and in vivo/immunohistochemical studies were performed.

Main Results:

• NORAD knockdown significantly promoted MM cell apoptosis and induced G1 phase cell cycle arrest.
• Knockdown of NORAD inhibited MM cell proliferation both in vitro and in vivo.
• Mechanistic studies revealed NORAD exerts its pro-tumorigenic effects through the BMP6/P-ERK1/2 signaling axis.

Conclusions:

• NORAD functions as an oncogene in multiple myeloma.
• NORAD promotes MM progression by inhibiting apoptosis and cell cycle arrest via the BMP6/P-ERK1/2 pathway.
• Targeting NORAD represents a potential therapeutic strategy for MM.